Pulse Biosciences, Inc. (PLSE)
USD 17.83
(-7.33%)
USD 17.83
(-7.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 43.57 Million USD | -6.92% |
| 2022 | 46.81 Million USD | -25.06% |
| 2021 | 62.46 Million USD | 25.02% |
| 2020 | 49.96 Million USD | 4.19% |
| 2019 | 47.95 Million USD | 26.32% |
| 2018 | 37.96 Million USD | 47.06% |
| 2017 | 25.81 Million USD | 169.29% |
| 2016 | 9.58 Million USD | 114.55% |
| 2015 | 4.46 Million USD | 768.77% |
| 2014 | 514.28 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 13.65 Million USD | 19.15% |
| 2024 Q2 | 11.46 Million USD | 11.09% |
| 2024 Q1 | 10.31 Million USD | -15.64% |
| 2023 FY | 42.36 Million USD | -9.5% |
| 2023 Q4 | 12.22 Million USD | 8.68% |
| 2023 Q3 | 11.25 Million USD | 10.02% |
| 2023 Q1 | 9.56 Million USD | 28.44% |
| 2023 Q2 | 10.22 Million USD | 6.95% |
| 2022 Q3 | 9.62 Million USD | -25.59% |
| 2022 Q2 | 12.93 Million USD | -23.04% |
| 2022 FY | 46.81 Million USD | -25.06% |
| 2022 Q1 | 16.8 Million USD | 11.96% |
| 2022 Q4 | 7.44 Million USD | -22.65% |
| 2021 Q2 | 14.8 Million USD | -20.08% |
| 2021 Q4 | 15.01 Million USD | 6.32% |
| 2021 Q1 | 18.52 Million USD | 34.67% |
| 2021 FY | 62.46 Million USD | 25.02% |
| 2021 Q3 | 14.12 Million USD | -4.63% |
| 2020 Q4 | 13.75 Million USD | 6.59% |
| 2020 Q1 | 11.95 Million USD | -14.21% |
| 2020 Q2 | 11.35 Million USD | -4.99% |
| 2020 Q3 | 12.9 Million USD | 13.66% |
| 2020 FY | 49.96 Million USD | 4.19% |
| 2019 Q1 | 10.41 Million USD | 14.9% |
| 2019 FY | 47.95 Million USD | 26.32% |
| 2019 Q4 | 13.93 Million USD | 16.43% |
| 2019 Q3 | 11.96 Million USD | 2.7% |
| 2019 Q2 | 11.64 Million USD | 11.9% |
| 2018 Q3 | 10.87 Million USD | 16.98% |
| 2018 Q2 | 9.3 Million USD | 6.6% |
| 2018 FY | 37.96 Million USD | 47.06% |
| 2018 Q1 | 8.72 Million USD | -1.21% |
| 2018 Q4 | 9.06 Million USD | -16.72% |
| 2017 Q2 | 6.22 Million USD | 92.18% |
| 2017 Q1 | 3.23 Million USD | 13.86% |
| 2017 Q3 | 7.52 Million USD | 20.96% |
| 2017 Q4 | 8.83 Million USD | 17.36% |
| 2017 FY | 25.81 Million USD | 169.29% |
| 2016 Q1 | 1.68 Million USD | 9.71% |
| 2016 FY | 9.58 Million USD | 114.55% |
| 2016 Q4 | 2.84 Million USD | 1.61% |
| 2016 Q3 | 2.79 Million USD | 23.75% |
| 2016 Q2 | 2.26 Million USD | 34.26% |
| 2015 Q4 | 1.53 Million USD | 24.39% |
| 2015 Q1 | 743 Thousand USD | 84.68% |
| 2015 Q3 | 1.23 Million USD | 29.08% |
| 2015 FY | 4.46 Million USD | 768.77% |
| 2015 Q2 | 956 Thousand USD | 28.67% |
| 2014 Q4 | 402.3 Thousand USD | 0.0% |
| 2014 FY | 514.28 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | 58.21% |
| AngioDynamics, Inc. | 252.41 Million USD | 82.737% |
| AtriCure, Inc. | 327.05 Million USD | 86.677% |
| Avinger, Inc. | 18.63 Million USD | -133.791% |
| Azenta, Inc. | 336.26 Million USD | 87.042% |
| BioLife Solutions, Inc. | 117.57 Million USD | 62.94% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 97.612% |
| Daxor Corporation | 1.28 Million USD | -3302.85% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | -80.125% |
| Femasys Inc. | 15.2 Million USD | -186.665% |
| GlucoTrack, Inc. | 7.1 Million USD | -513.373% |
| Harvard Bioscience, Inc. | 58.58 Million USD | 25.618% |
| Hologic, Inc. | 1.34 Billion USD | 96.761% |
| ICU Medical, Inc. | 717.04 Million USD | 93.923% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 98.529% |
| KORU Medical Systems, Inc. | 26.1 Million USD | -66.9% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | 51.765% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 36615.851% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 36615.851% |
| Masimo Corporation | 867 Million USD | 94.974% |
| Microbot Medical Inc. | 9.85 Million USD | -342.151% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | -136.557% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 90.526% |
| Nephros, Inc. | 9.78 Million USD | -345.36% |
| NovoCure Limited | 613.92 Million USD | 92.902% |
| NEXGEL, Inc. | 4.09 Million USD | -963.818% |
| NEXGEL, Inc. | 4.09 Million USD | -963.818% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | 57.382% |
| OraSure Technologies, Inc. | 125.34 Million USD | 65.236% |
| Pro-Dex, Inc. | 7.37 Million USD | -490.594% |
| Predictive Oncology Inc. | 15.22 Million USD | -186.115% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | -411.305% |
| QuidelOrtho Corporation | 1.35 Billion USD | 96.785% |
| Repligen Corporation | 261.12 Million USD | 83.313% |
| Sanara MedTech Inc. | 61.12 Million USD | 28.716% |
| STAAR Surgical Company | 224.55 Million USD | 80.595% |
| Sharps Technology, Inc. | 10.12 Million USD | -330.29% |
| Utah Medical Products, Inc. | 13.26 Million USD | -228.588% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 97.571% |
| Jin Medical International Ltd. | 3.91 Million USD | -1012.271% |